Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Vaxart Inc (VXRT)

Vaxart Inc (VXRT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])

Fundamentals

See More
  • Market Capitalization, $K 183,450
  • Shares Outstanding, K 241,414
  • Annual Sales, $ 237,260 K
  • Annual Income, $ 16,330 K
  • EBIT $ 18 M
  • EBITDA $ 26 M
  • 60-Month Beta 1.31
  • Price/Sales 0.76
  • Price/Cash Flow 7.11
  • Price/Book 1.99
  • Price/Earnings ttm 12.50
  • Earnings Per Share ttm 0.06
  • Most Recent Earnings $0.24 on 03/12/26
  • Next Earnings Date 05/12/26 [--]
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year $-0.07
  • Growth Rate Est. (year over year) +1,427,242.86%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.5555 +37.61%
on 03/30/26
0.7799 -1.99%
on 04/20/26
+0.1264 (+19.81%)
since 03/20/26
3-Month
0.5100 +49.88%
on 02/13/26
0.8196 -6.73%
on 03/05/26
+0.1044 (+15.82%)
since 01/21/26
52-Week
0.2606 +193.32%
on 07/09/25
0.8449 -9.53%
on 01/12/26
+0.4463 (+140.30%)
since 04/21/25

Most Recent Stories

More News
Vaxart Announces Share Purchase Agreement for up to $25 Million with Lincoln Park Capital

SOUTH SAN FRANCISCO, Calif., April 17, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral vaccines...

VXRT : 0.7790 (+2.51%)
Vaxart Provides Business Update and Reports Full Year 2025 Financial Results

Topline data from 400-person sentinel cohort of the Phase 2b COVID-19 trial anticipated early Q2 2026 Published positive clinical results in the first quarter of 2026 demonstrating oral norovirus...

VXRT : 0.7790 (+2.51%)
Vaxart to Host Upcoming Conference Calls

Full year 2025 business update and financial results conference call to be held March 12 at 4:30 p.m. ET Stockholder fireside chat to be held on March 13 at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif.,...

VXRT : 0.7790 (+2.51%)
Vaxart to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026

SOUTH SAN FRANCISCO, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range of oral vaccines based on its proprietary delivery...

VXRT : 0.7790 (+2.51%)
The 3 Penny Stocks You Swore You’d Never Buy (But You’ll Check Anyway)

Investors can use a free MarketBeat screener to find popular penny stocks; here are three stocks that may offer speculative upside for risk-tolerant investors

OUST : 28.98 (+6.78%)
MVIS : 0.6828 (-2.39%)
DVLT : 0.7689 (+4.26%)
INVZ : 0.6726 (+1.99%)
VXRT : 0.7790 (+2.51%)
LAZR : 0.1884 (-13.46%)
Vaxart Publishes Positive Data for its Oral Bivalent Norovirus Candidate in Lactating Women and Their Infants

Vaccine was safe and well-tolerated and led to a significant increase in norovirus-specific antibodies in serum and breast milk Norovirus-specific IgA in infant stool correlated with breast milk IgA,...

VXRT : 0.7790 (+2.51%)
Vaxart to Participate in the Global BioInnovation Forum on January 13, 2026

SOUTH SAN FRANCISCO, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart or “the Company”), a clinical-stage biotechnology company developing a range of oral recombinant pill...

VXRT : 0.7790 (+2.51%)
Vaxart Provides Business Update and Reports Third Quarter 2025 Financial Results

Entered into an exclusive license agreement with Dynavax for the Company’s COVID-19 oral pill vaccine candidate for potential cumulative proceeds of up to $700 million plus royalties Completed enrollment...

VXRT : 0.7790 (+2.51%)
Vaxart to Host Upcoming Conference Calls

Third quarter 2025 results conference call to be held on November 13 at 4:30 p.m. ET Stockholder fireside chat to be held on November 18 at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., Nov. 07,...

VXRT : 0.7790 (+2.51%)
Dynavax Reports Third Quarter 2025 Financial Results and Announces New $100 Million Share Repurchase Program

EMERYVILLE, Calif. , Nov. 5, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines,...

DVAX : 15.50 (unch)
VXRT : 0.7790 (+2.51%)

Business Summary

Vaxart, Inc. is a clinical-stage company developing a range of oral recombinant vaccines based on its proprietary delivery platform. The company's vaccines are administered using convenient room temperature-stable tablets that can be stored and shipped without refrigeration and eliminate risk of needle-stick...

See More

Key Turning Points

3rd Resistance Point 0.8704
2nd Resistance Point 0.8252
1st Resistance Point 0.7925
Last Price 0.7600
1st Support Level 0.7146
2nd Support Level 0.6694
3rd Support Level 0.6367

See More

52-Week High 0.8449
Last Price 0.7600
Fibonacci 61.8% 0.6217
Fibonacci 50% 0.5527
Fibonacci 38.2% 0.4838
52-Week Low 0.2606

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.